載入...
Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.
To establish a baseline for care and overall survival (OS) based upon contemporary first-line treatments prescribed in the era before the introduction of immune checkpoint inhibitors, for people with metastatic non-small cell lung cancer (NSCLC) without common actionable mutations.Using a nationally...
Na minha lista:
Main Authors: | , , , , , , |
---|---|
格式: | Artigo |
語言: | Inglês |
出版: |
Public Library of Science (PLoS)
2017-01-01
|
叢編: | PLoS ONE |
在線閱讀: | http://europepmc.org/articles/PMC5482433?pdf=render |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|